According to the partners, the new diagnostics platform would enable clinical labs to skip numerous liquid-handling steps, which would improve efficiency and shorten the time to receive test results. 3M Bioanalytical Technologies will supply Third Wave with the microfluidic technology.
Terms of the agreement were not disclosed.